About Arvinas
Arvinas is a publicly listed company based in New Haven (United States) founded in 2013. Arvinas has raised $100.12 million across 4 funding rounds from investors including New Leaf Venture Partners, Orbimed and RA Capital. The company has 430 employees. Its chief executive, as recorded, is John Houston. Its website arvinas.com draws about 11 thousand monthly visits. Arvinas offers products and services including PROTAC Platform, ARV-393, and ARV-102. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Arvinas, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Developer of small molecule drugs to target and degrade disease causing proteins. It offer therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its protein degradation platform uses bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs), to target proteins for removal from the cell. PROTACs recruit an E3 ubiquitin ligase to a specific targeted protein, thereby labelling that protein for elimination by the UbiquitinProteasome System (UPS).
- Headquarters New Haven, United States
- Employees 430
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website arvinas.com
- Social LinkedIn
- Legal Name Arvinas, Inc.
- Annual Revenue$262.6 M (USD)-0.3as on Dec 31, 2025
- Net Profit-$80.8 M (USD)59.38as on Dec 31, 2025
- EBITDA-$109.7 M (USD)45.2as on Dec 31, 2025
- Total Equity Funding$100.12M (USD)
in 4 rounds
- Latest Funding Round$32.5M (USD), Post-IPO
Jul 2019
- InvestorsNew Leaf Venture Partners
& 10 more
- Employee Count430
Products & Services of Arvinas
Arvinas offers a comprehensive portfolio of products and services, including PROTAC Platform, ARV-393, and ARV-102.
Platform for targeted protein degradation in drug discovery and therapies.
Investigational therapy for BCL6 degradation in cancer treatment.
Oral therapy targeting LRRK2 for neuroscience applications.
Funding Insights of Arvinas
Arvinas has successfully raised a total of $100.12M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100.12M
- Total Rounds 4
- Last Round Post-IPO — $32.5M
- First Round $3.51M
(Jul 2013)
- Investors Count 11
All 4 funding rounds of Arvinas with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $32.5M | Post-IPO | – | – | – |
| Apr 2018 | $55M | Series C | – | Nextech Invest | |
| Oct 2015 | $41.61M | Series B | – | Canaan, 5AM Ventures | – |
| Jul 2013 | $3.51M | Seed | – | 5AM Ventures, Connecticut Innovations | – |
11 investors in total: 11 institutional.
Investors in Arvinas
Arvinas has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Healthcare innovation is supported through venture capital investments. | sironacap.com | |||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
VC firm investing in seed & early stage companies in the US | 2006 | elmvc.com | New Haven, United States |
Investor details for Arvinas
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arvinas
165 people are tracked at Arvinas (81 in leadership, 16 in board & advisors, 68 in team); the tracked headcount is 430.
| Name | Role | Group |
|---|---|---|
John Houston | CEO | Leadership |
Ian Taylor | Chief Scientific Officer | Leadership |
Kelly Page | SVP, Global Head of Oncology Strategy & Program Leadership | Leadership |
Kyle Fraser | Director, Translational Sciences - Neuroscience | Leadership |
Joseph Sciacchitano | US Head, Senior Director Patient Support Services | Market Access | Leadership |
Ilaria Conti | Vice President Clinical Research | Leadership |
Tim Bye | Senior Director, Commercial Operations | Leadership |
Marcia Dougan Moore | VP, Development Operations | Leadership |
Dina Smith | Executive Director, Market Access | Leadership |
Angela M. Cacace | VP, Neuroscience & Platform Biology | Leadership |
Randy Teel | VP, Corporate Development | Leadership |
Steve Weiss | VP, Human Resources | Leadership |
Deborah Kroeger | Senior Director, Talent Acquisition | Leadership |
Stacey Versavel | Senior Medical Director, Neurology, Medical Affairs | Leadership |
Gaurav Arora | Executive Director- Commercial Strategy And Development | Leadership |
James Gregory | Associate Director, Neuroscience | Leadership |
Katie Smith | Director, Oncology | Leadership |
Halie Beckert | Associate Director, Eh&s And Site Operations | Leadership |
Adam W Hendricson | Associate Director, Neurology | Leadership |
Liz Duperret | Associate Director, Oncology Translational Science And Clinical Biomarkers | Leadership |
145 more people are available in the full profile.
Complete people profiles for Arvinas
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arvinas
Arvinas is a publicly listed company on the NASDAQ with ticker symbol ARVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Sep 2018
- Listed onNASDAQ: ARVN
- Listed entityArvinas, Inc.
- Exchange sectorHealth technology
- ISINUS04335A1051
- Share price$6.84 (-8.19% on the day) · 2026-10-13
- Market capitalisation$447.2M
- Price to earnings42.6
- EPS (diluted, trailing year)$0.16
- Volume (last session)852,893
Financials of Arvinas
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $262.6M | -$80.8M | -$109.7M |
| 2024 | $263.4M | -$198.9M | -$200.2M |
| 2023 | $78.5M | -$367.3M | -$394.8M |
| 2022 | $131.4M | -$282.5M | -$255.0M |
| 2021 | $53.6M | -$191.0M | -$184.0M |
Detailed financial statements for Arvinas
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arvinas
4 dated milestones of Arvinas across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Arvinas is founded.
- Funding First funding round of $3.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $32.5M.
Competitors of Arvinas
Arvinas has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Arvinas
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arvinas
The website of Arvinas (arvinas.com) receives about 11.1K visits a month and ranks #1,825,332 among all websites worldwide, #2,492 in Biotechnology and Pharmaceuticals.
- Monthly visits11.1K
▼ 21.6% vs previous month
- Unique visitors6.5K
per month
- Global rank#1,825,332
among all websites
- Category rank#2,492
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit30 sec
- DevicesDesktop 48% · Mobile 52%
Websites whose visitors overlap most with Arvinas. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pharmexec.com | pharmexec.com | 100% | #565,102 | – | |
| oncologypipeline.com | 99% | 76.4K | #510,302 | View details | |
| biopharmadive.com | 99% | 680.7K | #208,628 | View details | |
| bioct.org | 99% | 11K | #2,362,632 | View details | |
| endpts.com | 99% | 8.4K | #3,077,209 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Arvinas
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Arvinas (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arvinas
Complete news archive for Arvinas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arvinas
Arvinas was founded in 2013.
Arvinas is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
John Houston is the CEO of Arvinas, as recorded in our data.
Arvinas is a funded company, having raised a total of $100.12M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3.51M, raised on Jul 2013.
Arvinas has 430 employees.
Annual revenue of Arvinas is $262.6M as on Dec 31, 2025.
Developer of small molecule drugs to target and degrade disease causing proteins. It offer therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its protein degradation platform uses bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs), to target proteins for removal from the cell. PROTACs recruit an E3 ubiquitin ligase to a specific targeted protein, thereby labelling that protein for elimination by the UbiquitinProteasome System (UPS).
Arvinas offers PROTAC Platform, ARV-393, and ARV-102.
Yes, Arvinas is publicly traded on NASDAQ under the ticker symbol ARVN.
Arvinas has 11 investors. Key investors include New Leaf Venture Partners, Orbimed, RA Capital, Canaan, and Elm Street Ventures.
Arvinas operates through Arvinas, Inc..